Ani Pharmaceuticals (ANIP) Deferred Taxes (2014 - 2026)

Ani Pharmaceuticals has disclosed Deferred Taxes across 13 years of filings, most recently posting -$4.9 million for Q2 2026.

• In Q2 2026, Deferred Taxes fell 39.65% year-over-year to -$4.9 million; the TTM figure through Jun 2026 stood at $18.7 million (up 162.37% YoY), while the FY2025 annual figure was $14.2 million, up 164.97% from the prior year.
• Deferred Taxes came in at -$4.9 million for Q2 2026 at Ani Pharmaceuticals, down from $2.5 million in the prior quarter.
• In the past five years, Deferred Taxes ranged from a high of $18.8 million in Q3 2025 to a low of -$17.5 million in Q4 2024.
• Average Deferred Taxes over 5 years is -$2.1 million, with a median of -$2.8 million recorded in 2022.
• Year-over-year, Deferred Taxes tumbled 2575.27% in 2022 and jumped 436.44% in 2025.
• Over 5 years, Deferred Taxes stood at -$1.6 million in 2022, then plunged by 413.6% to -$8.3 million in 2023, then tumbled by 110.04% to -$17.5 million in 2024, then soared by 113.44% to $2.4 million in 2025, then slumped by 309.59% to -$4.9 million in 2026.
• Per Business Quant data, the three most recent Deferred Taxes figures were -$4.9 million in Q2 2026, $2.5 million in Q1 2026, and $2.4 million in Q4 2025.